Romy Kallas is a Rheumatology/Immunology physician affiliated with Hospital for Special Surgery. OpenAlex indexes 16 publications with 324 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
535 E 70th St
New York, NY 100214823
Telephone
212-774-2189Provider last certified this registry record 25 Jul 2023.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- UCB, Inc.Program year20251 payment
- Aurinia Pharma U.S., Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32%Folate Analog Metabolic Inhibitor26.1%Methotrexate100%Part D≥14 patientsNonsteroidal Anti-inflammatory Drug5.8%Celecoxib100%Part D<11 patientsMetabolism & gastrointestinal
29.9%Corticosteroid19.1%Prednisone100%Part D≥13 patientsAntidiarrheal microorganisms5.8%Folic Acid100%Part D<11 patients+ 1 more class in this area
Antiparasitic
16.6%Antimalarial16.6%Hydroxychloroquine Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus
Current Rheumatology Reports
2026 - POS0200 TYPE I INTERFERON ACTIVITY IN PERSISTENTLY ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PATIENTS WITH OR WITHOUT LUPUS: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CLINICAL DATABASE AND REPOSITORY (“REGISTRY”)
Annals of the Rheumatic Diseases
2025 - Trajectory of Damage Accrual in Systemic Lupus Erythematosus Based on Ethnicity and Socioeconomic Factors
The Journal of Rheumatology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lockshin, MD
Hospital for Special Surgery
Lionel Ivashkiv, MD
Hospital for Special Surgery
Vivian Bykerk, VIVIAN, BYKERK, MD
Hospital for Special Surgery
Jane Salmon, MD
Hospital for Special Surgery
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”